Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.

[1]  Bénédicte Lebrun-Vignes,et al.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.

[2]  Daniel Bernstein,et al.  Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. , 2018, Annual review of pharmacology and toxicology.

[3]  W. Hwang,et al.  Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[4]  Nenad Bursac,et al.  Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues , 2017, Nature Communications.

[5]  Sarah Jeanfavre,et al.  Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass , 2017, Science.

[6]  C. Yin,et al.  Comparative Gene Expression Analyses Reveal Distinct Molecular Signatures between Differentially Reprogrammed Cardiomyocytes. , 2017, Cell reports.

[7]  Douglas A. Chapnick,et al.  Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1–Parkin pathway and modulate cellular drug response , 2017, The Journal of Biological Chemistry.

[8]  Praveen Shukla,et al.  High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells , 2017, Science Translational Medicine.

[9]  D. Serie,et al.  The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes , 2017, Clinical and Translational Medicine.

[10]  Friedrich Rippmann,et al.  KinMap: a web-based tool for interactive navigation through human kinome data , 2017, BMC Bioinformatics.

[11]  David G Strauss,et al.  Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[13]  Russ B Altman,et al.  Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.

[14]  L. Calvo,et al.  Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study , 2016, Clinical and Translational Oncology.

[15]  S. Yamanaka,et al.  Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes , 2016, Scientific Reports.

[16]  Jie-ning Zhu,et al.  CDK6 mediates the effect of attenuation of miR-1 on provoking cardiomyocyte hypertrophy , 2015, Molecular and Cellular Biochemistry.

[17]  I. Karakikes,et al.  Induced Pluripotent Stem Cell–Derived Cardiomyocytes: A New and Versatile Human In Vitro Cardiomyocyte Model Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Insights Into Molecular, Cellular, and Functional Phenotypes , 2015 .

[18]  Matthew E. Welsch,et al.  Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis , 2014, eLife.

[19]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[20]  P. Faust,et al.  Cholesterol biosynthesis and ER stress in peroxisome deficiency. , 2014, Biochimie.

[21]  Petra C. Kienesberger,et al.  Hypoxic Regulation of Hand1 Controls the Fetal-Neonatal Switch in Cardiac Metabolism , 2013, PLoS biology.

[22]  Torsten Doenst,et al.  Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.

[23]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[24]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[25]  Stefan A. Mann,et al.  hERG K(+) channels: structure, function, and clinical significance. , 2012, Physiological reviews.

[26]  Loïc Dayon,et al.  Relative Protein Quantification by MS/MS Using the Tandem Mass Tag Technology , 2012, Quantitative Methods in Proteomics.

[27]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[28]  Susan Cheng,et al.  Reversible cardiomyopathy associated with sunitinib and sorafenib. , 2011, The New England journal of medicine.

[29]  C. Lynch,et al.  Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[30]  B. Humphreys,et al.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. , 2010, Seminars in nephrology.

[31]  V. Chinchilli,et al.  Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice. , 2010 .

[32]  M. Ahluwalia,et al.  Reversible cardiotoxicity with tyrosine kinase inhibitors. , 2010, Clinical advances in hematology & oncology : H&O.

[33]  HuiCheng,et al.  Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics , 2010 .

[34]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[35]  J. Stypmann,et al.  Reversible regulation of the retinoblastoma protein/E2F-1 pathway during "reverse cardiac remodelling" after ventricular unloading. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[36]  Matthew D. Young,et al.  Gene ontology analysis for RNA-seq: accounting for selection bias , 2010, Genome Biology.

[37]  P. Bhargava.  VEGF kinase inhibitors: how do they cause hypertension? , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[38]  M. Hori,et al.  Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure , 2009, Journal of hypertension.

[39]  M. Chen,et al.  Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase , 2009, Clinical and translational science.

[40]  A. Ardavanis,et al.  Cardiotoxicity induced by tyrosine kinase inhibitors , 2009, Acta oncologica.

[41]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B. Jessen,et al.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Wendy Leisenring,et al.  Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. , 2008, Journal of the National Cancer Institute.

[44]  P. Busk,et al.  Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy , 2008, Cell proliferation.

[45]  G. Rosano,et al.  Cardiac metabolism in myocardial ischemia. , 2008, Current pharmaceutical design.

[46]  M. Chen,et al.  Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics , 2008, Circulation.

[47]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[48]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[49]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[50]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[51]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[52]  D. Roden.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[53]  A. Garnier,et al.  Energy metabolism in heart failure , 2004, The Journal of physiology.

[54]  Greg Hamerly,et al.  Learning the k in k-means , 2003, NIPS.

[55]  Y. Fujii‐Kuriyama,et al.  Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  R. Reneman,et al.  Fatty acid homeostasis in the normoxic and ischemic heart. , 1992, Physiological reviews.

[57]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.